Spyre Therapeutics, Inc. - Common Stock SYRE 深 滬
等待開盤 10-28 09:30:00 美东时间
24.755
+1.385
+5.93%
華盛通- 最 高25.00
- 今 開24.01
- 成交量 59.45万股
- 最 低 23.76
- 昨 收 23.37
- 總市值 14.95亿
- 52周最高 40.26
- 市盈率 靜 --
- 換手率 0.98%
- 52周最低 10.91
- 委 比 9.47%
- 總股本 6040.10万
- 歷史最高 318.75
- 量 比 1.11
- 振 幅 5.31%
- 歷史最低 2.66
- 每 手 1
- 風險率 5.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Spyre Therapeutics Releases New Data From Its Phase 1 Study Of SPY072, An anti-TL1a Antibody For Rheumatic Diseases Showing SPY072 Was Well Tolerated, Maintained Strong Tl1a Suppression, And Supports Quarterly Or Twice-Yearly Dosing
Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease ("IBD") and
10-24 20:04
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
Spyre Therapeutics announced scientific presentations at the ACR Convergence Congress, sharing Phase 1 data on SPY072, an anti-TL1A agent for rheumatic diseases. The data showed SPY072 is well-tolerated, with a PK profile supporting quarterly or twice-yearly dosing, and suppressed free TL1A at the lowest dose. Additionally, preclinical data demonstrated SPY072's efficacy, meeting or exceeding etanercept in a rodent arthritis model, supporting ong...
10-24 12:00
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
Spyre Therapeutics, a clinical-stage biotech company focused on treating inflammatory bowel disease and other immune-mediated conditions, announce the closing of its underwritten public offering. The company sold 17,094,594 shares, including 2,229,729 additional shares due to underwriters' option exercise, at $18.50 per share, resulting in approximately $316.2 million in gross proceeds. Jefferies, TD Securities, Leerink Partners, and Stifel acted...
10-15 20:15
Spyre Therapeutics Reveals Proposed Public Offering of its Common Stock And Pre-Funded Warrants; No Size Disclosed
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization,
10-14 04:03
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. announced the pricing of its underwritten public offering of 14,864,865 shares of common stock at $18.50 per share, with expected gross proceeds of approximately $275 million. The offering includes an option for underwriters to purchase up to an additional 2,229,729 shares. Spyre, a clinical-stage biotech company focused on antibody engineering and immune-mediated diseases...
10-14 01:07
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
Spyre Therapeutics announced scientific presentations at the UEGW Congress, highlighting interim Phase 1 results for SPY002, an anti-TL1A agent for IBD, showing it is well-tolerated with a potential for quarterly or twice-yearly dosing. The company also presented preclinical data demonstrating the superior efficacy of combination therapies targeting α4β7, TL1A, and IL-23 in colitis models, supporting the ongoing SKYLINE-UC Phase 2 study. Full ses...
10-05 13:00
美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
09-29 09:15
Deutsche Bank Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $43
Deutsche Bank analyst David Hoang initiates coverage on Spyre Therapeutics (NASDAQ: SYRE) with a Buy rating and announces Price Target of $43.
09-26 19:38
美股大行评级 | Arete Research上调百度"买入"评级，目标价143美元；瑞银上调蔚来"买入"评级，目标价升至8.5美元
今日重点评级关注：HC Wainwright & Co.：维持Orion Energy Sys"买入"评级，目标价从2美元升至20美元；高盛：维持Amylyx Pharmaceuticals"买入"评级，目标价从10美元升至20美元
09-17 10:15
First Patient Dosed In Spyre Therapeutics Phase 2 Trial Of SPY072 For Rheumatic Diseases
Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory
09-15 20:02
